Abstract:Purpose of review: (1) To provide commentary on the 2017 update to the Kidney Disease Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD); (2) to apply the evidence-based guideline update for implementation within the Canadian health care system; (3) to provide comment on the care of children with chronic kidney disease (CKD); and (4) to identify research priorities for Canadian patients. Sources of information: The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. Methods: The commentary committee co-chairs selected potential members based on their knowledge of the Canadian kidney community, aiming for wide representation from relevant disciplines, academic and community centers, and different geographical regions. Key findings: We agreed with many of the recommendations in the clinical practice guideline on the diagnosis, evaluation, prevention, and treatment of CKD-MBD. However, based on the uncommon occurrence of abnormalities in calcium and phosphate and the low likelihood of severe abnormalities in parathyroid hormone (PTH), we recommend against screening and monitoring levels of calcium, phosphate, PTH, and alkaline phosphatase in adults with CKD G3. We suggest and recommend monitoring these parameters in adults with CKD G4 and G5, respectively. In children, we agree that monitoring for CKD-MBD should begin in CKD G2, but we suggest measuring ionized calcium, rather than total calcium or calcium adjusted for albumin. With regard to vitamin D, we suggest against routine screening for vitamin D deficiency in adults with CKD G3-G5 and G1T-G5T and suggest following population health recommendations for adequate vitamin D intake. We recommend that the measurement and management of bone mineral density (BMD) be according to general population guidelines in CKD G3 and G3T, but we suggest against routine BMD testing in CKD G4-G5, CKD G4T-5T, and in children with CKD. Based on insufficient data, we also recommend against routine bone biopsy in clinical practice for adults with CKD or CKD-T, or in children with CKD, although we consider it an important research tool. Limitations: The committee relied on the evidence summaries produced by KDIGO. The CSN committee did not replicate or update the systematic reviews.

Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases

Management and Treatment of Glomerular Diseases (part 2): Conclusions from A Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns

Renal and Urinary Conditions: Glomerulonephritis

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis

Glomerulonephritis: immunopathogenesis and immunotherapy

New perspectives in treatment of glomerulonephritis

Advances in primary glomerulonephritis

KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary

Comments on the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anticoagulant Therapy in Patients with Membranous Nephropathy.

The Kidney Disease: improving Global Outcomes website: comparison of guidelines as a tool for harmonization.

A New Initiative in Nephrology: 'kidney Disease: Improving Global Outcomes'.

Inspiration from the immunosuppression section of KDIGO clinical practice guideline for the care of kidney transplant recipients

Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group

Management of minimal-change disease and idiopathic focal segmental glomerulosclerosis in adults:interpretation of KDIGO guideline

CKD therapy to improve outcomes of immune-mediated glomerular diseases

Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder

Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)

Primary Glomerulonephritis in Mainland China: an Overview.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59